All News

4 March 2009

XOMA Initiates Phase 2a Clinical Trial With XOMA 052 in Patients With Rheumatoid ArthritisAntibodies

3 March 2009

FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead ProductAntibodies

2 March 2009

Xencor and Pfizer Enter into Antibody Technology Licensing AgreementAntibodies

2 March 2009

ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.Antibodies

2 March 2009

ImmunoGen, Inc. Earns Milestone Payment with Genentech’s Start of Trastuzumab-DM1 (T-DM1) Phase III Clinical Testing; Other T-DM1 Progress ReportedAntibodies

2 March 2009

Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of MesotheliomaAntibodies

27 February 2009

Crucell’s Revolutionary Antibody for Universal Therapy Against FluAntibodies

27 February 2009

BioInvent Presents Positive Preclinical Data for BI-505 in MyelomaAntibodies

27 February 2009

MabThera approved in the EU for patients with chronic lymphocytic leukaemiaAntibodies

26 February 2009

Arzerra(TM) (ofatumumab) MAA Accepted by EMEAAntibodies

25 February 2009

Implicit Licenses Clinical Stage Antibody Program From LillyAntibodies

25 February 2009

Seattle Genetics Completes Enrollment in Lintuzumab Phase IIb Clinical Trial for Patients with AcuteAntibodies

24 February 2009

Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 MillionAntibodies

24 February 2009

ESBATech’s Antibody Fragment ESBA105 Enters Phase IIa in Uveitis StudyAntibodies

24 February 2009

PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense MeetingAntibodies

24 February 2009

NasVax and Ramot Announce Licensing Agreement on Novel Immunotherapies for Treatment of Alzheimer’s DiseaseAntibodies

23 February 2009

Xencor and CSL Limited Establish Antibody Optimization CollaborationAntibodies

23 February 2009

BioInvent and ThromboGenics Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) ProphylaxisAntibodies

19 February 2009

Seattle Genetics Initiates Pivotal Trial of SGN-35 for Hodgkin LymphomaAntibodies

19 February 2009

European Medicines Agency Recommends Suspension of Marketing Authorization for RaptivaAntibodies

18 February 2009

FDA Accepts Amgen’s Submission and Files Biologics License Application for DenosumabAntibodies

17 February 2009

Clinical study started with VAP-1 antibody in rheumatoid arthritis patientsAntibodies

11 February 2009

Peregrine Pharmaceuticals’ Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer StudyAntibodies

10 February 2009

Progenics Selects Subcutaneous Form of PRO 140, a Novel HIV Antibody Therapy, for Further DevelopmentAntibodies

10 February 2009

XOMA and Takeda Expand CollaborationAntibodies

10 February 2009

The French Biopharmaceutical Group LFB Has Announced the First-in-Man Injections of Its First Two Therapeutic Monoclonal Antibodies and the Filing of BLAs for a New-Generation Immunoglobulin and a FibrinogenAntibodies

9 February 2009

Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)Antibodies

6 February 2009

UCB’s meeting with U.S. FDA defines path forward for Cimzia(R) in rheumatoid arthritisAntibodies

5 February 2009

GlaxoSmithKile and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood CancerAntibodies

5 February 2009

Ablynx Announces Second Extension of its Nanobody(R) Drug Discovery and Development AlianceAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

TSLP Pipeline Review

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Mesothelin-Targeted Immunotherapy Pipeline Review

Her3-Targeted Immunotherapy Pipeline Review

Ranibizumab (Lucentis) Biosimilars Pipeline Review

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

CD40 Agonists & CD40/L Antagonists Pipeline Review

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review